Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

Clinical trial NCT04383938 · COMPLETED

Trial details

NCT number: NCT04383938
Sponsor: Aprea Therapeutics
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Bladder Cancer Gastric Cancer Non Small Cell Lung Cancer NSCLC Urothelial Carcinoma Advanced Solid Tumor

Start date: 2020-06-25
Primary completion: 2022-04-30
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.